ARCHIVES

ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | March 21, 2008

Download PDF Visit The Full Archive

Related Articles

Miami HIV Trials Unit Forced To Turn Some Patients Away

January 10, 1992

Zevalin Regimen Better Than Rituximab Alone For NHL

June 29, 2001

Contact Planned To Encourage Insurers To Reimburse For Cancer Screening

November 28, 1975

FDA Vs. NCI: Nothing Has Changed; Chabner “Frustrated” By Flutamide Delay

October 21, 1988

Interactive RPGs Deadline Is Feb. 20

December 13, 1991

Pittsburgh Cancer Institute Wins SPORE Grant For Lung Cancer, For Three Major Projects.

July 20, 2001